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Abstract 
Background: MeCP2—a chromatin‑binding protein associated with Rett syndrome—has two main isoforms, 
MeCP2‑E1 and MeCP2‑E2, differing in a few N‑terminal amino acid residues. Previous studies have shown brain 
region‑specific expression of these isoforms which, in addition to their different cellular localization and differential 
expression during brain development, suggest that they may also have non‑overlapping molecular mechanisms. 
However, differential functions of MeCP2‑E1 and E2 remain largely unexplored.
Results: Here, we show that the N‑terminal domains (NTD) of MeCP2‑E1 and E2 modulate the ability of the methyl‑
binding domain (MBD) to interact with DNA as well as influencing the turn‑over rates, binding dynamics, response to 
neuronal depolarization, and circadian oscillations of the two isoforms. Our proteomics data indicate that both iso‑
forms exhibit unique interacting protein partners. Moreover, genome‑wide analysis using ChIP‑seq provide evidence 
for a shared as well as a specific regulation of different sets of genes.
Conclusions: Our study supports the idea that Rett syndrome might arise from simultaneous impairment of cellular 
processes involving non‑overlapping functions of MECP2 isoforms. For instance, MeCP2‑E1 mutations might impact 
stimuli‑dependent chromatin regulation, while MeCP2‑E2 mutations could result in aberrant ribosomal expression. 
Overall, our findings provide insight into the functional complexity of MeCP2 by dissecting differential aspects of its 
two isoforms.
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Background
Methyl CpG-binding protein 2 (MeCP2) was first iden-
tified through its ability to bind methylated DNA [1]. 
Mutations in the MECP2 gene were later associated 
with Rett syndrome (RTT; OMIM 312750), a severe 
neurological disorder that is among the most common 
causes of intellectual disability in females [2].
MeCP2 gene has four exons than can be alternatively 
spliced to produce two transcripts. The transcript skip-
ping exon 2 has translation initiation in exon 1 and 
encodes MeCP2-E1. This isoform is slightly longer (498 
amino acids in humans) and has 21 unique N-terminal 
amino acids. When exon 2 is included in the transcript, 
translation initiates in exon 2 to give rise to MeCP2-E2, 
a shorter variant (486 amino acids in humans) with 9 
unique N-terminal amino acids [3, 4]. The remaining 
sequence is identical for both isoforms (Figs.  1a and 
2a).
MeCP2-E1 is likely the ancestral form of the protein, 
as orthologues are present across vertebrate evolution, 
whereas orthologous sequences of the exon 2 coding 
region have only been found in mammalian genomes 
[5]. Although splicing variants often encode proteins 
with different functions, in the case of MeCP2-E1 and 
E2 isoforms, this remains still controversial [6, 7]. The 
presence of a polyalanine tract followed by a polygly-
cine tract in E1 N-terminal domain (NTD) could be an 
indication of a potential functional difference [8]. In 
this regard, polyalanine domains within various protein 
families are thought to have a convergent origin, sug-
gesting that a specific function for these tracts has been 
selected by evolutionary pressure [9]. The existence of 
Fig. 1 Biophysical characterization of the MeCP2‑E1 and E2 NTD‑MBD domain interaction with DNA. a Schematic representation of the MeCP2‑E1 
and E2 isoforms depicting the unique NTD amino acid sequences and shared domains. b Fluorescence thermal denaturation curves for E1 and E2 
NTD‑MBD protein fragments in the presence of unmethylated and mCpG‑dsDNA. Unfolding traces were fitted considering a two‑state unfolding 
model. c Unfolding stability parameters obtained from thermal denaturations followed by intrinsic tryptophan fluorescence. d Calorimetric 
titrations of E1 and E2 NTD‑MBD proteins interacting with dsDNA plots show the thermograms (thermal power as a function of time) and the 
binding isotherms (normalized heats as a function of the dsDNA/protein molar ratio). e Buffer‑independent dsDNA binding parameters  (Kd, 
dissociation constant; ΔG: Gibbs free energy of interaction; ΔH: enthalpy of interaction; −TΔS: entropic contribution of interaction; ΔCP: heat 
capacity of interaction; nH: number of protons exchanged upon complex formation) obtained from calorimetric titrations at pH 7
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non-overlapping functions of the E1 and E2 isoforms 
is supported by a difference in their relative abundance 
during development and in diverse regions of the brain 
[10, 11]. Moreover, Rett syndrome-causing mutations 
described so far involve solely the E1 isoform, and iso-
form-specific mouse knockouts show Rett-related phe-
notypes for E1 knockout but not for E2, suggesting that 
E2 does not functionally compensate for the lack of E1 
[12, 13]. However, the high degree of structural simi-
larity between MeCP2 isoforms points towards a high 
extent of functional overlapping, and some findings 
reinforce this idea. For instance, E2 expressed at levels 
comparable to those of E1 was reported to prevent key 
Rett-like phenotypes in mice models of Rett syndrome, 
indicating that part of the difference between isoforms 
Fig. 2 Isoforms N‑terminal processing, turn‑over rates, and dynamics. a Mass spectrometry sequencing of the N‑terminal end of the MeCP2 protein 
(in vitro). N‑terminal peptide coverage alignment chart and high‑resolution mass spectra showing N‑methionine excision (NME) and N‑acetylation 
(NA) of the N‑termini of MeCP2‑E1 and MeCP2‑E2. NA (+42 Da) of N‑terminus amino acid is shown highlighted in yellow. b–d Cycloheximide‑chase 
assays of the E1 and E2 MeCP2 isoforms. Densitometries and representative western blots performed after cycloheximide treatments of b 
SH‑SY5Y cells overexpressing (OE) E1 and E2 isoforms fused to GFP, c differentiated SH‑SY5Y, and d rat cultured cortical neurons with detection of 
endogenous E1 and E2 isoforms. e Densitometric analysis and representative western blots showing endogenous E1 and E2 levels in frontal cortices 
of mice euthanized at 12 a.m. and 12 p.m. f KCL depolarization and representative Western blots analysis of total endogenous MeCP2 of cultured 
cortical neurons and E1 and E2 of transfected cultured cortical neurons overexpressing Flag‑MeCP2‑E1 or E2. Represented data are mean ± S.E.M. 
(n = 7–8). * P < 0.05 two‑tailed Mann–Whitney test. MeCP2 levels were normalized using β actin and/or histone H3
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could simply be related to the disparity in temporospa-
tial expression and protein levels [7].
Given the poorly understood nature of the structural 
and functional differences between E1 and E2 isoforms, 
we decided to investigate this further. Our study compre-
hensively describes for the first time differences between 
MeCP2 isoforms, using various complementary biophys-
ical, biochemical, and genomic approaches. This work 
provides a detailed framework for the further under-
standing of the many fold functional aspects of MeCP2, 
thus shedding light onto the pathophysiology of Rett syn-
drome and other neurological disorders.
Results
Biophysical characterization of MeCP2 isoforms N‑terminal 
domains
As mentioned in the introduction, the different function-
ality of the MeCP2 isoforms has long remained contro-
versial. However, there are many indirect hints to suggest 
otherwise, including a different pattern of expression 
during mouse brain development (Additional file 1: Fig. 
S1 A) [11] and various evidences previously mentioned. 
Interestingly, the two MeCP2 isoforms differ only in their 
N-terminal domain (NTD) (Fig.  1a), which has been 
previously described to lack any DNA-specific binding 
structure, but has the ability to stabilize the neighboring 
methyl-binding domain (MBD) and its binding to meth-
ylated DNA [14, 15]. A partial folding of this unstruc-
tured region might contribute to the interaction with 
double-stranded DNA (dsDNA), thus having a differen-
tial impact on E1 and E2 binding properties. Therefore, 
we decided to compare the different biophysical proper-
ties of E1 and E2 NTDs. Constructs consisting of the E1 
or E2 specific NTD followed by the MBD were analyzed 
as previously described [15]. Thermal unfolding studies 
of E1/NTD-MBD and E2/NTD-MBD (Fig.  1b) indicate 
that E1 isoform shows a slightly lower mid-transition 
temperature (temperature at which 50% of the protein 
is unfolded, Tm) in all situations considered according to 
the two-state unfolding model (Fig. 1c; Additional file 1: 
Fig. S1B), showing a slightly lower structural stability.
Following the same trend, E1 isoform also shows a 
diminished unfolding enthalpy (ΔH) (Fig. 1c), indicating 
a lower cooperativity in the thermal unfolding, suggest-
ing that amino acid residues located at the NTD might be 
important for the stability of the folded regions located 
in the MBD. The nature of protein–DNA interactions 
was further assessed by determining their thermody-
namic profile with isothermal titration calorimetry (ITC), 
considering a single binding site model [15] (Fig. 1d, e). 
Results show that compared to E2, E1 exhibits ninefold 
lower binding affinity (higher dissociation constant, Kd) 
for methylated dsDNA and fivefold lower binding affinity 
for unmethylated dsDNA, thus resulting in E1 isoform 
having a slightly lower discrimination capability for meth-
ylated/unmethylated dsDNA (Fig.  1e). Strikingly, the 
main intermolecular DNA-binding driving forces for the 
two isoforms are of different nature, displaying opposed 
thermodynamic binding profiles: dsDNA interaction 
with E1 is enthalpically driven and with E2 is entropically 
driven; thus, while E1 interacts with favorable binding 
enthalpy (ΔH) and unfavorable binding entropy (−TΔS), 
E2 interacts with negligible binding enthalpy and favora-
ble binding entropy (Fig.  1e). Therefore, the interaction 
of E1 isoform with dsDNA is mainly driven by specific 
interactions between the protein and the dsDNA (i.e., 
hydrogen bonds and electrostatic interactions), and the 
interaction of E2 isoform with dsDNA is mainly driven 
by unspecific interactions (i.e., hydrophobic desolvation 
and steric arrangements). In addition, E1 isoform exhib-
its a larger binding heat capacity (ΔCP) and the formation 
of its complex with dsDNA releases a larger number of 
protons (nH). Overall, these observations indicate that 
the amino acid residues at the N-terminal regions of E1 
and E2 NTDs have significant influence not only on pro-
tein stability, but also on the interaction with the dsDNA: 
E1 is slightly less stable and exhibits lower affinity for 
dsDNA than E2 isoform. Fluorescence recovery after 
photobleaching (FRAP) data for the two isoforms sup-
ports this, with E1 having a more rapid recovery trajec-
tory than E2, suggesting looser binding, although t-half 
and mobile fractions were not significantly different 
(Additional file 1: Fig. S1C). These properties could also 
be reflecting a differential ability of MeCP2 isoforms to 
interact with other molecules, different turn-over rate, 
intracellular trafficking, or susceptibility to undergo post-
translational modifications.
Higher MeCP2‑E1 protein turn‑over in neuronal systems 
reflects its involvement in dynamic processes
MeCP2 is an intrinsically disordered protein (IDP) [16], 
thus highly susceptible to proteolytic degradation. The 
lower affinity of the E1 NTD-MBD region for DNA or its 
lower folding stability might reflect a higher presence in 
solution or the occurrence of a larger exposed surface to 
be targeted for proteasomal degradation [17]. Therefore, 
we decided to compare the half-lives of the two MeCP2 
isoforms in different neuronal systems. The end-terminal 
amino acid has great impact in protein degradation [18], 
and thus, we first assessed the N-terminal processing of 
both proteins. The NTDs were expressed in HEK293T 
cells, and purified and analyzed by mass spectrometry 
(MS). Our previous MS sequencing of the N-terminal 
tael of MeCP2-E1 [5] showed no peptides with N-ter-
minal methionine (NM), indicating complete NM exci-
sion (NME) at the first residue (P1) position (Fig. 2a Top 
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panel). Acetylation of the initial alanine residue (P′1) 
after NME was observed.
In addition, we observed some peptide reads with ala-
nine 1, or alanine 1 and 2, or alanine 1–4, or 1–5 excised 
and acetylation of the subsequent alanine. For MeCP2-
E2, on the other hand, we found reads in which N-ter-
minal methionine (P1 position) is retained and acetylated 
and few peptide reads with NME and acetylation of the 
penultimate valine (P’1) (Fig. 2a Bottom panel). All post-
translational modifications (PTMs) reported received 
Ascores of 1000. The complete methionine excision 
and the presence of alanine as first residues in E1 sup-
port a faster turn-over rate of this isoform, compared 
to the E2 bearing a methionine or valine as N-terminal 
amino acids [19]. We then decided to test this possibil-
ity by performing cycloheximide (CHX) chase assays and 
Western blot (WB) in three different contexts: undiffer-
entiated SH-SY5Y neuroblastoma cells transfected with 
E1- and E2-EGFP (enhanced green fluorescent protein) 
fusion proteins (Fig. 2b), differentiated SH-SY5Y (Fig. 2c), 
Additional file  2: Fig. S2A), and DIV7 rat cortical neu-
rons (Fig.  2d). These experiments consistently showed 
a tendency of E1 to be degraded faster than E2, both at 
the endogenous level and when the isoforms were over-
expressed in cell cultures (detected using specific in 
house-made antibodies, Additional file 2: Fig. S2B). Our 
results prompted us to investigate if MeCP2 isoforms 
would show differential behavior in two highly dynamic 
neuronal settings, the circadian cycle and neuronal acti-
vation. First, we took advantage of the system which we 
reported previously displaying total MeCP2 24  h oscil-
lations [20]. Analysis of frontal cortices obtained at 12 
a.m. and 12 p.m. shows a noticeable 30% reduction of E1 
protein level at 12 p.m., while E2 levels remain similar 
at these two times (Fig. 2e). The second scenario involv-
ing MeCP2 dynamics was neuronal activation after KCl 
exposure. Protein levels were measured at different time 
points after depolarization (55  mM KCl). The inability 
of the MeCP2-E2 antibody to detect this isoform in rat 
neurons prompted us to first determine the endogenous 
levels of total MeCP2 after treatment. Due to the high 
E1 abundance compared to E2, this mostly corresponds 
to the E1 isoform. Next, we assessed the two isoforms’ 
dynamics by transfecting cultured rat neurons with flag-
tagged E1 and E2. The results show a fast increase of total 
MeCP2 levels immediately after KCl treatment followed 
by a decrease to basal levels at around 4  h after treat-
ment (Fig. 2f ). Interestingly, we observe a completely dif-
ferent pattern between MeCP2 isoforms. As expected, 
E1 shows a trend similar to that of total MeCP2, rapid 
upregulation upon depolarization that is maintained 
during 3–4 h, and then, protein levels decrease to reach, 
in this case, approximately 50% of the initial E1 levels 
(Fig. 2f ). By contrast, E2 shows a stable pattern, exhibit-
ing levels similar to those of non-treated cells throughout 
the whole duration of the experiment (Fig.  2f ). Hence, 
our data confirm the existence of different dynamics of 
MeCP2 isoforms that are consistent with a different role 
of the proteins within the neuronal context.
Genome‑wide distribution of MeCP2‑E1 and MeCP2‑E2 
isoforms
The differences described between E1 and E2 in terms of 
their affinity for methylated DNA and dynamics might 
have an influence on and/or reflect a differential genomic 
distribution. Chromatin immunoprecipitation and 
sequencing (ChIP-seq) of E1 and E2 in frontal cortices 
of mice euthanized at 12 a.m. and 12 p.m. showed broad 
distributions for both isoforms, as previously noted for 
total MeCP2 (Additional file 3: Fig. S3A and B, [21–23]. 
The overall distribution of the isoforms along different 
genomic regions was similar (FDR ≤ 0.001, SICER algo-
rithm: window 600 bp; gap 200 bp; Fig. 3a). Despite the 
similar isoform’s general distribution, we were able to 
identify different significantly enriched binding motifs 
specific for E1 (using E2 bound peaks as background), 
GCT GAG C (e-value: 1.2 e−145), and GCC ACA GCA 
(e-value: 2 e−99) indicating a differential binding site 
preference (Fig.  3b). As MeCP2 has been described to 
be a transcriptional regulator, we analyzed the distribu-
tion of MeCP2 isoforms around transcribed regions. The 
average binding profiles of E1 and E2 to regions span-
ning 1.5 kb upstream of transcription start sites (TSS) to 
1.5 kb downstream transcription end sites (TES) demon-
strate a consistently similar binding pattern for both iso-
forms, with a marked depletion at TSS and a peak at TES 
(Fig. 3c).
Interestingly, a closer inspection around TSS regions 
(Fig.  3d) revealed a marked depletion of E2 precisely at 
the TSS. In contrast, the E1 isoform is depleted before 
the TSS and corresponding to the −1 nucleosome region, 
with a slight increase on the TSS at 12 a.m. that decreases 
at 12 p.m. These results suggest a differentiated role of 
the two isoforms in shaping the chromatin structure 
around the TSS.
We then clustered the genes based on their MeCP2 
occupancy. Heatmap clusters and profiles for the log2 
ratio plots failed to reveal any differential binding of the 
isoforms to specific gene clusters (data not shown); how-
ever, we detected daily differences for each isoform occu-
pancy throughout gene bodies (Fig. 4a). For instance, E1 
cluster 1 showed a flat profile at 12 a.m. and an increased 
binding at 12 p.m. (Figure 4b). In the case of E2, cluster 4 
exhibited an increased binding at 12 p.m. compared to 12 
a.m., while cluster 5 displayed lower binding at 12 p.m. 
(Figure  4c). Functional pathways associated with genes 
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present in each cluster were analyzed using the Kyoto 
encyclopedia of genes and genomes (KEGG) (Fig. 4d left 
graphs). All three clusters were enriched in genes related 
to sensory transduction like olfaction or taste, and with 
histone proteins (E1 was associated with genes encoding 
H2A family members (p value: 1.16  e−06) and E2 mainly 
with members of the histone cluster 1 (cluster 4 p value: 
1.65  e−13 and cluster 5 p value: 2.23  e−27). MeCP2 iso-
form-specific enrichments were related to neuroactive 
ligand–receptor interaction in E1 and ribosomal proteins 
in E2. Interestingly, cluster 5 contains several genes asso-
ciated with the neurodegenerative diseases Huntington 
(p value: 4.17  e−08), Parkinson (p value: 9.87  e−06) and 
Alzheimer (p value: 9.15  e−06). ChIP-qPCR validations 
of randomly selected genes of each cluster confirmed the 
general trends observed in our ChIP-seq-analysis, despite 
the very slight variations of the isoforms’ occupancies 
during the day (Fig. 4d right graphs). Overall, our results 
suggest that beyond the common functions in which 
both isoforms are involved, they regulate different sets 
of genes and display distinct dynamics on their genomic 
occupancy, reinforcing the existence of non-overlapping 
roles.
MeCP2‑E1 and E2 protein partners
IDP proteins are characterized by their inability to 
acquire a stable secondary structure when free in solu-
tion. This confers the structural flexibility that enables 
them to serve as scaffolds for the recruitment of partners 
and thus function as interacting hubs [24]. Interestingly, 
Fig. 3 Genome‑wide distribution and dynamics of MeCP2 isoforms. a Bar plot depicting the distributions of regions enriched in the MeCP2 
isoforms across eight defined genomic features. b DNA‑binding motifs enriched for MeCP2‑E1 (and excluding E2) shown as motif logos based on 
aligned, over‑represented patterns found in the binding sites. The overall height of each stack indicates the sequence conservation at that position 
(measured in bits), whereas the height of symbols within the stack reflects the relative frequency of the corresponding amino or nucleic acid at that 
position. c ChIP‑seq average profiles across 3 Kb upstream the TSS and 3 Kb downstream the TES of genic regions occupied by E1 at 12 a.m. and 12 
p.m. (top) and E2 at 12 a.m. and 12 p.m. (bottom). d Details of the previous representations focusing in a 6 Kb region surrounding the TSS of E1 and 
E2 bound genes (top and bottom panels, respectively)
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Fig. 4 MeCP2‑E1 and E2 isoforms display diurnal dynamic genomic binding. a Heatmaps representing the log2 ratios obtained for E1 and E2 
ChIP experiments; each column is divided into five clusters using the k‑means algorithm. Protein occupancy is represented by color intensity, 
where the darker the color, the higher the protein enrichment. b Comparison of E1 enrichment at 12 a.m. vs. 12 p.m. showing occupancy 
differences in different clusters of interest. c Heatmap depicting the E2 12 a.m. vs. 12 p.m. shows a dynamic binding in clusters 4 and 5 (yellow 
and orange, respectively). d Left graphs: top‑enriched functional pathways (−log10 (P)) of genes included in dynamic E1 and E2 gene clusters 
[Kyoto encyclopedia of genes and genomes (KEGG)]. Right graphs: ChIP‑qPCR results validating MeCP2‑E1 and E2 variations in occupancy of genes 
included in each of the gene clusters obtained
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IDPs, including MeCP2, usually acquire ordered struc-
tures upon binding to their interacting partners, allowing 
the exposure of molecular recognition features (MoRFs) 
to further make contacts with other molecules [25, 26]. 
Thus, the possibility exists that the aforementioned E1 
and E2 differences in unfolding temperature and affinity 
for DNA could expose differential interacting surfaces. 
These attributes together with their previously discussed 
expression patterns [3, 4, 27] raise the possibility that E1 
and E2 might be involved in non-overlapping molecu-
lar functions that perhaps could be defined through the 
identification of their protein interactors. Therefore, we 
decided to perform a comprehensive proteomic analysis 
to look for MeCP2-E1 and E2 protein partners. Endog-
enous E1 and E2 from whole brain lysates were immuno-
precipitated, using normal rabbit IgG and blocking of E1 
and E2 antibodies with blocking peptides were used as 
negative controls. Co-immunoprecipitated proteins were 
separated by SDS-PAGE and different gel fractions sec-
tioned for protein identification by mass spectrometric 
analysis (Fig. 5a).
We chose proteins identified by at least 2 significantly 
matching peptides which were absent from the negative 
controls. This filter rendered 40 interacting proteins for 
Fig. 5 MeCP2‑E1 and E2 interacting proteins. a Schematic workflow of the proteomic analysis. b, c Proteins partners identified for each isoform. 
d Selected pathways enriched in E1 and E2 interacting proteins as identified by functional clustering (DAVID Gene Ontology Bioinformatics 
Resources). Newly identified interactors are shown in black and previously identified interactors are highlighted in orange
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the E1 isoform and 7 for E2 (Fig. 5b, c). As a good vali-
dation for our approach, we detected several previously 
described MeCP2 interactors (Fig. 5b, c, interactors high-
lighted in orange [28–34]).
Functional clustering of co-eluted proteins (DAVID 
[35]) uncovered functional enrichments, especially for 
E1 (Fig.  5d). E1 co-eluted proteins are highly enriched 
for β-Tubulins, the building blocks of microtubules, and 
microtubule-associated proteins such Adducin 1 (Add1) 
or microtubule-associated protein 6 (Map6). Importantly, 
microtubule assembly initiates from the centrosome, 
organelle associated with MeCP2 function in microtu-
bule stability, and mitotic spindle organization [36–38]. 
Proteins related to mRNA splicing and mRNA process-
ing were also highly represented among E1 partners (for 
example, 116  kDa U5 small nuclear ribonucleoprotein 
component [Eftud2], Heterogeneous nuclear ribonucleo-
proteins L [Hnrnpl] or DEAD (Asp-Glu-Ala-Asp) box 
polypeptides 5 and 17 [Ddx5 and Ddx17]). MeCP2 func-
tions on RNA splicing or mRNA processing have been 
previously described [33, 39, 40], but still lack deep inves-
tigation. As we expected, functions related to chromatin 
regulation are also enriched among MeCP2-E1 partners, 
as we found the nucleosome-core histone H2A and the 
variant H3.3, the chromatin regulators Brg1 associated 
factor 170 (BAF170), member of the switch/sucrose non-
fermenting (SWI/SNF) complex, and MTA2, subunit of 
the nucleosome remodeling deacetylase (NuRD) com-
plex [41]. Functional network analysis (STRINGv10 [42]) 
revealed a higher than expected number of connections 
between all E1 and E2 interactors (Additional file 4: Fig. 
S4; p value < 0.001), and suggests the participation of E2 
in processes similar to those involving E1, but through 
the interaction with a different set of protein partners. In 
this regard, among E2 interactors, we found the microtu-
bule-associated protein RP/EB family members 1 and 3 
(Mapre1 and Mapre3), important for microtubule organ-
ization [43]. The E2 interactor fused in sarcoma (FUS) is 
involved in mRNA processing, with Mecp2 being one of 
its known target genes [44]. In the chromatin regulation 
group, we found that E2 specifically interacts with two 
recently described MeCP2 protein partners: Transducin-
β-like 1 (Tbl1) and Tbl1-related 1 (Tbl1r1), components 
of the nuclear receptor co-repressor (N-CoR) complex 
[28, 29]. Interestingly, E2 also interacts with the polymer-
ase I transcription and release factor (Ptrf ), and protein 
involved in ribosomal DNA (rDNA) transcription [45].
E1 co-eluted proteins include spectrin β1, lamin B2, the 
band 4.1 proteins B and N, and matrin 3 (the latter was 
previously reported to interact with E1 in neuronal nuclei 
[31]), components of the nuclear matrix [46], classically 
defined as a fibrogranular structure which consists of 
nucleoskeleton/nuclear lamina networks and associated 
proteins [47, 48]. Of note, one of the best characterized 
components of the nuclear matrix is the attached region-
binding protein (ARBP), a chicken MeCP2 orthologue 
[49] that binds methylated DNA within matrix attach-
ment region (MAR) elements [48, 50].
Overall, the lack of shared protein partners by the 
MeCP2-E1 and E2 isoforms suggests their involvement in 
similar general mechanisms like RNA processing, chro-
matin control of transcription, or microtubule regulation, 
but performing non-redundant functions through the 
interaction with different partners.
Discussion
The existence of mutations affecting only the MeCP2-E1 
isoform in Rett patients [e.g., p.Ala2Val; [13, 51]] sug-
gest that endogenous E2 expression cannot compensate 
for the lack of functional E1. An important question thus 
arises as to whether this is simply related to the lower lev-
els of E2 found in neurons [27] or it is due to the exist-
ence of E1-specific functions that cannot be provided by 
the E2 isoform. The different cellular distribution of the 
two isoforms and their distribution during brain develop-
ment (Additional file  1: Fig. S1) also suggest a different 
functionality.
The NTD is the only structural feature that differs 
between the two MeCP2 isoforms, and currently, there is 
a lack of information regarding any potential functional 
difference between E1 and E2 NTDs. The NTD of these 
isoforms has generically been described as a highly disor-
dered region able to acquire secondary structure, as dem-
onstrated by the coil-to-helix transitions exhibited in the 
presence of hydrogen-bond stabilizers [26]. Such confor-
mational transitions contribute to enhancing the MBD 
affinity for DNA [14]. To the best of our knowledge, the 
biophysical characterization of the interaction of NTD-
MBD fragments of the two MeCP2 isoforms with DNA 
is the first of its kind (Fig. 1). Most of MeCP2 functions 
rely on its ability to bind nucleic acids, and in this regard, 
these results uncover a fundamental ninefold difference 
in affinity for DNA of E2 over E1 isoform. This could be 
one of the basic structural features responsible for shap-
ing the functional discrepancies between the isoforms.
The main differences observed here between the 
MeCP2 isoforms can be summarized as follows: E1 (the 
major isoform of MeCP2 in neurons) shows a lower 
DNA-binding affinity and a lower structural stability 
(Fig. 1). E1 also exhibits a higher basal degradation rate 
in various neuronal settings and enhanced dynamic 
fluctuations of protein levels via diurnal rhythm oscil-
lations and neuronal depolarization (Fig.  2). Within 
a neuronal context, these attributes are especially 
interesting given the peculiar chromatin relation-
ship between MeCP2 and the linker histone H1 in 
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this tissue. Under normal conditions, neurons express 
MeCP2 to near histone-octamer levels and contain half 
the amount of H1. By contrast, when MeCP2 is not 
expressed, H1 returns to the levels which are observed 
in other somatic tissues [52]. Therefore, it is likely 
that MeCP2-E1 could function within this setting as a 
DNA-methylation-dependent highly dynamic linker 
histone, needed to allow for rapid chromatin structural 
changes in response to external stimuli. This is particu-
larly important in neurons, given their versatile ability 
to readily modify gene expression as a result of their 
unique methylome [53, 54].
In this regard, signal transduction from the cell surface 
to the genome often relies on the cytoskeleton–nucle-
oskeleton–chromatin interconnection [46]. Importantly, 
we have identified MeCP2-E1 and E2 protein partners 
associated with every part of this system: the cytoskel-
eton (i.e., tubulins, Map6, and Mapre1 and 3), nuclear 
envelope/matrix-associated proteins (Lamin B2, Band 
4.1 proteins, Spectrin, or Matrin 3), and chromatin (his-
tone proteins, Hp1γ, Mta2, or Baf170) (Fig. 5). Our find-
ings open up the possibility of MeCP2 functioning as an 
important player in signal transduction. In particular, E1 
could play a prominent role in the neuron-specific nucle-
oskeleton–chromatin connection, due to its remarkable 
abundance and the dynamism observed upon the applica-
tion of external stimuli such as neuronal depolarization.
Because of its higher abundance, E1 appears to exhibit 
a more dynamic behavior; however, E2 also exhibits an 
oscillating genomic-binding nature. Surprisingly, most of 
the daily MeCP2 isoform-binding differences observed 
overlap with genes encoding for sensorial receptors, such 
as olfactory (ORs) and taste (TASRs) receptors (Fig. 4d). 
This seemingly counterintuitive result is very interesting 
as preliminary observations have shown expression of 
ORs and TASRs in brain regions not related to the direct 
detection of odors and flavors [55]. The study of the so-
called “ectopic ORs” (outside olfactory epithelium) is in 
its infancy, but apparently, they act as chemoreceptors 
which are important to maintain cellular homeostasis, 
and some of them are able to activate complex cellular 
responses mediated by neurotransmitters or hormones 
[55]. The expression of olfactory receptors has been 
described to be upregulated in MeCP2 KO mice and 
downregulated in mice overexpressing the protein. These 
data support a potential role for MeCP2 in transcrip-
tional regulation of these genes in different regions of the 
brain structures such as cerebellum, amygdala, and hypo-
thalamus [21]. More importantly, the expression of these 
receptors in brain is altered in neurodegenerative dis-
eases such as Parkinson’s, Alzheimer’s and in prefrontal 
cortex in schizophrenia [55], disorders in which MeCP2 
expression has been also observed to be dysregulated 
[16]. Our ChIP-seq results reinforce this MeCP2 function 
and add a dynamic component to it.
Quite unexpectedly, all gene clusters displaying 
dynamic diurnal binding of the two MeCP2 isoforms 
were also enriched in gene-encoding replication-depend-
ent (RD) histones. Expression of RD histones has been 
recently detected in terminally differentiated cells and tis-
sues, including neurons and brain [56, 57]. Some of these 
genes encode histone isotypes with a certain sequence 
divergence [56], and could possibly affect the histone 
interactions within the nucleosome. Further analyses 
will be required to assess if MeCP2 has any regulatory 
effect on the expression of such genes, but it is tempting 
to speculate a possible role in the generation of variant 
nucleosomes present in adult brain [56].
An additional distinctive function for MeCP2-E2 which 
could be inferred from our results has to do with ribo-
somal gene expression regulation. Our co-immuno-pre-
cipitation experiment demonstrated the interaction of E2 
with Ptrf (Fig. 5c). Transcription of ribosomal genes has 
been reported to be dependent on the DNA methylation 
status [58] and occurs through the formation of nucleo-
tide loops linking initiation and termination gene regions, 
process in which Ptrf participation is essential [45]. Our 
ChIP-seq results provide evidence for a dynamic MeCP2-
E2 genomic binding to ribosomal genes (Fig. 4). In sup-
port to our results, MeCP2 has been previously linked to 
nucleolar changes during neuronal maturation [59].
Another observation made through our ChIP-seq 
analysis is that the two isoforms possess significant dif-
ferences in DNA-binding site preference; E1 targets are 
significantly enriched for the DNA motifs GCT GAG C 
and GCC ACA GCA. Interestingly, the latter motif con-
tains the trinucleotide CAC, described by Lagger and 
colleagues to be, when methylated, a high affinity-bind-
ing site for MeCP2 in brain [22].
Conclusion
Overall, the present work provides support to the 
notion that Rett syndrome arises from the simultane-
ous impairment of different cellular functions involving 
both MeCP2 isoforms. For instance, mutations of E1 may 
have a larger impact in neuronal chromatin structure and 
stimuli-dependent gene expression dynamics. We have 
previously described in MeCP2 KO mice a decrease in 
the circadian gene oscillations of the brain-derived neu-
rotrophic factor (Bdnf) and somatostatin (Sst) genes [20]. 
By contrast, similar mutations in E2 could be involved in 
the deregulation of ribosomal expression or microtubule 
control.
The seemingly contradictory literature available to 
date regarding the degree of functional overlapping of 
MeCP2 isoforms is likely the result of the lack of studies 
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carried out on the endogenous native proteins. Over-
all, our results provide strong support for the existence 
of both different and overlapping functions between the 
two. Importantly, our study uncovers some functional 
aspects of MeCP2 that were previously unknown. It 
opens the door to further investigation that will be help-
ful to understand the role of this complex protein in the 
healthy state and the consequences of its deregulation in 
Rett syndrome and other neurological disorders.
Methods
Animals and cell lines
The Mecp2-null mouse strain [60] was purchased 
from Jackson Laboratories (003890B6.129P2(C)-
Mecp2 < tm1.1Bird >/J), maintained on a CD1 back-
ground, and genotyped as described in [61]. C57BL/6 
mice and Sprague–Dawley rats were maintained under 
standard animal house conditions (12  h dark–light 
cycles on ad libitum food and water intake). Cortical pri-
mary neurons were prepared from Sprague–Dawley rat 
embryos as described previously [62]. For depolarization 
assay, neuronal activity was blocked by pre-treatment 
of the cells with 1  mM tetrodotoxin (TTX), 100  mM 
DL-2-amino-5-phosphonovalerate (APV), and 20  mM 
6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX). Depo-
larization was achieved by 30  min exposure to 55  mM 
KCl in Tyrode buffer. Transfections with plasmids 
expressing Flag-MeCP2 isoforms (kind gift from Angus 
Wilson [63]) were performed using the Amaxa rat neu-
ron nucleofector kit (Lonza) following the manufacturer’s 
instructions.
Human cell lines SH-SY5Y and HEK 294 were obtained 
from the American Type Culture Collection (ATCC) and 
were maintained in DMEM supplemented with 10% FBS, 
penicillin–streptomycin and l-glutamine (Gibco) in a 
37 °C, 5%  CO2 humidified incubator. Differentiation was 
performed as previously described [64]. Cells were trans-
fected with MeCP2-E1 and MeCP2-E2 C-terminal GFP 
[5] using Lipofectamine 3000 (Invitrogen). Cyclohex-
imide (CHX) treatments were performed 48  h after 
transfection.
Western blot
Mouse brains (brain development) for each development 
time period were used to prepare western blot samples 
as per [65]. Nuclear extracts of HEK293 cells express-
ing the 3 × Flag versions of E1 and E2 were used to pre-
pare serial dilutions and calculate MeCP2-E1/MeCP2-E2 
ratios. Frozen frontal cortices (circadian) and cell pel-
lets (CHX) were homogenized on Laemmli buffer 3% 
B-Mercaptoethanol. In all experiments, proteins were 
separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) [66] and transferred onto 
nitrocellulose membranes (GE Healthcare), and block-
ing by incubating in 5% skimmed milk in PBS with 0.1% 
Tween 20. Membranes were incubated with specific anti-
bodies, either overnight at 4  °C or for 1 h at room tem-
perature. Antibodies and dilutions used were as follows: 
MeCP2 1:5000, β-actin 1:20,000, Histone H4 1:20,000 
Histone H3 1:20,000 (Abcam), Flag 1:5000 (Sigma-
Aldrich), EGFP 1:1000 (Thermo Fisher), in house rabbit 
polyclonal antibodies MeCP2 E1 1:1000 and E2 1:500. 
Fluorescent secondary antibodies were (Li-Cor) 1:10,000. 
Densitometries were performed with Li-Cor Image Stu-
dio Light software.
Protein expression
Plasmids were transformed into BL21 (DE3) Star E. coli 
strain. Protein expression was induced with 1  mM iso-
propyl 1-thio-β-d-galactopyranoside (IPTG) at 18  °C 
overnight. Cells were sonicated and treated with ben-
zonase (Merck-Millipore). Proteins were purified using 
immobilized metal ion affinity chromatography (IMAC) 
in a HiTrap TALON column (GE-Healthcare Life Sci-
ences) with two washing steps before a 10–150 mM imi-
dazole elution gradient. Removal of the histidine-tag was 
performed with GST-tagged PreScission Protease (GE-
Healthcare). Further purification was performed using a 
HiTrap TALON column and a GST TALON column (GE-
Healthcare). The identity of all proteins was checked by 
mass spectrometry (4800plus MALDI-TOF/MS, Thermo 
Fisher). Stability and binding assays were performed at 
different pH and buffer conditions [50 mM Tris (pH 7–9), 
0–150  mM NaCl; 50  mM Pipes (pH 7); 50  mM Phos-
phate (pH 7)]. Buffer exchanges were performed using a 
10 kDa-pore size ultrafiltration device (Amicon centrifu-
gal filter, Merck-Millipore) at 4000 rpm and 4 °C.
Double‑stranded DNA
HPLC-purified single-stranded DNA fragments were 
purchased from Integrated DNA Technologies and 
annealed. Sequences correspond to the promoter IV of 
the mouse brain-derived neurotrophic factor (BDNF) 
[15].
Fluorescence spectroscopy
Thermal unfolding studies were performed in a Cary 
Eclipse fluorescence spectrophotometer (Varian—Agi-
lent) in three steps. Fluorescence emission spectra were 
recorded from 300 to 400  nm (excitation 290  nm and 
bandwidth 5 nm). Protein concentration was set at 5 µM. 
Thermal stability assays were performed at a heating rate 
of 1  °C/min and at the wavelength for maximal spec-
tral change (330  nm). Thermal unfolding experiments 
were analyzed considering a two-state unfolding model 
[15]. The stabilizing effect upon dsDNA interaction was 
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assessed performing thermal denaturations in the pres-
ence of methylated and unmethylated DNA (at 10  µM) 
under the same conditions.
Isothermal titration calorimetry (ITC)
Proteins–dsDNA interactions were characterized using 
an Auto-iTC200 microcalorimeter (MicroCal—Malvern 
Instruments). 3–5  µM protein was titrated with 50  µM 
dsDNA (2 µL titrant every 150 s). Interaction parameters 
were obtained as previously described [15]. Buffer-inde-
pendent binding parameters and protons released were 
determined by calorimetric titrations using buffers with 
different ionization enthalpies [15], and binding heat 
capacity was determined by calorimetric titrations at dif-
ferent temperatures.
Fluorescence recovery after photobleaching (FRAP)
MeCP2-E1 and MeCP2-E2 isoforms were expressed in 
HEK293T cells in chambered cover glass culture plates 
(Nunc™; NalgeNunc). Experiments were performed at 
37 °C and 5%  CO2. Confocal time-lapse images of frames 
(512 × 512 pixels) were captured at 488  nm excitation 
with 0.05 transmissions for GFP-tagged protein post-
bleach recovery. Images were recorded with a minimum 
of 10 pre-bleach frames, 250 µs bleach time with 405 nm 
laser line at 100% transmission, and 150 post-bleach 
frames were recorded at equal time intervals.
Cycloheximide‑chase assay
Cells were treated with 10  µg/mL of cycloheximide 
(Sigma-Aldrich) and harvested at the indicated times. 
Samples collected at each time point were then analyzed 
by western blot.
Mass spectrometry to determine MeCP2 PTMs
All protein samples were digested overnight at 37  °C 
with trypsin, using 50:1 protein:enzyme ratio. Digested 
peptide mixtures were desalted using  C18 reverse phase 
columns, and then loaded onto a 50  cm × 75  μm ID 
column with RSLC 2  μm  C18 packing material (EASY-
Spray, Thermo-Fisher) with an integrated emitter, and 
then eluted into a Q-Exactive™ Hybrid Quadrupole-
Orbitrap™ mass spectrometer (Thermo-Fisher) using an 
Easy-Spray nLC 1000 chromatography system (Thermo-
Fisher). The mass spectrometer was operated with 1 mass 
spectrometry (MS) spectrum followed by 10 MS/MS 
spectra in a data-dependent mode. The MS was acquired 
with a resolution of 70,000 FWHM (full width at half 
maximum), a target of 1 × 106 ions, and a maximum scan 
time of 120 ms. Using a relative collision energy of 27%, 
the MS/MS scans were acquired with a resolution of 
17,500 FWHM, a target of 1 × 106 ions, and a maximum 
scan time of 120  ms. A dynamic exclusion time of 15  s 
was used for the MS/MS scans. XCalibur 2.2 (Thermo-
Fisher Scientific) was used to acquire the raw data files 
and further processed with the PEAKS 7 search engine 
(Bioinformatics Solutions) using a database consisting of 
the wild-type MeCP2 constructs. Ascores were assigned 
for the peptides and PTMs using the PEAKS 7 software.
Chromatin immunoprecipitation
Mice were euthanized 6 and 18 h after first light stimu-
lus (12 a.m. and 12 p.m., respectively). One frontal cor-
tex was crosslinked in 1x PBS 0.5% formaldehyde at room 
temperature for 5 min and quenched by adding 0.125 M 
Glycine for 5 min. The tissue was centrifuge and washed 
twice with ice-cold PBS. The pellet was resuspended in 
1  mL ChIP lysis buffer [10  mM HEPES (pH7.9), 1.5  M 
 MgCl2, 10  mM KCl, 0.5  mM DTT, and 0.1% NP-40], 
dounce-homogenized (10 strokes), and incubated on 
ice for 20  min. Nuclei were centrifuged at 2500×g for 
5 min and resuspended in 300 µL of RIPA buffer [50 mM 
Tris–HCl (pH 8), 150 mM NaCl, 0.5% SDS, 0.5% Sodium 
deoxycholate, 1% Triton-100]. Suspension was sonicated 
in a Bioruptor (Diagenode) at high power for 15  min 
with 30  s on/off intervals. Chromatin was centrifuged 
at 16,000×g for 10  min. Supernatant was diluted ten 
times with RIPA buffer without SDS and pre-cleared for 
2 h with 20 µL of Dynabeads Protein G magnetic beads 
(Thermo Fisher). Eight microns of MeCP2 E1 and E2 
antibodies (produced in house, Additional file  2: Fig. 
S2B) and Normal Rabbit IgG (Cell Signaling Technolo-
gies) were bound to 25 µL of Dynabeads Protein G fol-
lowing the manufacturer’s instructions and incubated 1 h 
in PBS/5% BSA. Inmunoprecipitations were performed 
at 4  °C overnight while tumbling. Supernatants were 
discarded and beads washed twice with 1 mL of low salt 
buffer [50  mM Tris–HCl (pH 8.0), 150  mM NaCl, 0.1% 
SDS, 1% NP-40, 1 mM EDTA, 0.5% Sodium deoxycolate], 
twice with 1 mL of high salt buffer [50 mM Tris–HCl (pH 
8.0), 500 mM NaCl, 0.1% SDS, 1% NP-40, 1 mM EDTA, 
0.5% Sodium deoxycolate], twice with 1 mL of LiCl buffer 
[50 mM Tris–HCl (pH 8.0), 250 mM LiCl, 0.1% SDS, 1% 
NP-40, 1  mM EDTA, 0.5% sodium deoxycholate], and 
twice with 1 mL of TE. Chromatin was eluted in elution 
buffer (100  mM  NaHCO3, 1% SDS) and reversal of the 
crosslinking was carried out for 5 h at 65 °C. The samples 
were then incubated with proteinase K for 1  h at 65  °C 
and RNase A for 30 min at 42 °C. DNA was purified with 
a PCR purification kit (Qiagen).
Bioinformatics analysis of ChIP‑Seq data
ChIP-seq libraries were pooled and sequenced paired-
end 75 on a HiSeq 2500 (Illumina). We detected binding 
sites using SICER (window 600 bp, gap 200 bp) [67], and 
detected differential binding sites (e.g., E1 vs E2) with 
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the same tool. Peaks were called in each sample inde-
pendently. Increased and decreased peaks in the two 
replicates were then combined to provide reliable peaks, 
using MSPC  (10−4 and  10−8 thresholds on p values defin-
ing stringent and weak peaks, respectively [68]. Location 
of the peaks was performed with ChipSeeker [69] on 
mm10 annotation. For visualization purposes, ChIP sig-
nal has been normalized to input signal using the signal 
extraction scaling (SES) method [70]. RSAT peak-motif 
tool [71] was used detect over-represented motifs in the 
detected peaks. For cluster generation, we merged rep-
licates and computed the fold-change distribution along 
the gene body, the TSS, and the TES. We then com-
puted the fold-change distribution along each gene and 
clustered the genes into five groups using the k-means 
method. Pathway enrichment analysis was performed 
with WebGestalt [72].
qPCR
Each PCR was carried out in triplicate using SYBR Green 
PCR Master Mix (Applied Biosystems) and following the 
manufacturer’s instructions. Fluorescent signals were 
acquired by the Stratagene Mx3005P qPCR System (Agi-
lent Technologies), and primer sequences upon request.
Co‑immunoprecipitation and mass spectrometry
One whole brain/immunoprecipitation was processed 
as per [73] with slight modifications. MNase digestion 
was performed during 30  min at 37  °C with 150 units 
MNase (Worthington). After centrifugation, super-
natant was kept on ice and reaction was stopped by 
addition of EDTA (10  mM final concentration). The 
remaining pellet was resuspended in digestion buffer 
with 2  mM  CaCl2, and 50 ud MNase were added and 
incubated for 20 min at 37 °C. The reaction was stopped 
by addition of EDTA (10 mM final concentration), the 
sample was centrifuged and supernatant kept. Superna-
tant was pre-cleared for 1  h with 50 µL of Dynabeads 
Protein G magnetic beads (Thermo Fisher). Negative 
controls for the IP were obtained by blocking E1 and 
E2 paratopes with E1 and E2 specific peptides [E1: 
CAAAAPSGGG GGG EEER; E2: MVAGMLGLREEKC 
(New England Peptides)]. Antibodies were blocked 
during 45  min by tumbling at room temperature with 
a fivefold excess of the specific peptide. 10  µg of each 
antibody [E1, E1 blocked, E2, E2 blocked and normal 
rabbit IgG (Cell Signaling Technologies)] were bound 
to 50  µl of magnetic beads according to the manu-
facturer’s instructions. Immunoprecipitations were 
carried out overnight at 4  °C while tumbling. Anti-
body–protein complexes were washed and proteins 
eluted with 2x SDS buffer, boiled for 10  min and pro-
teins were run on SDS-PAGE. The gel was stained with 
Coomassie blue and different sections were excised 
for subsequent analysis. Mass spectrometry was then 
performed using a nano-HPLC system (Easy-nLC II, 
Thermo Fisher), coupled to the ESI source of an LTQ 
Orbitrap Velos (Thermo Fisher), using conditions 
described previously [74]. MS data were acquired using 
a data-dependent method. The data acquisition also 
utilized dynamic exclusion, with an exclusion window 
of 10  ppm and exclusion duration of 10  s. MS events 
used 60,000 resolution FTMS scans, and MS/MS events 
used ITMS scans, with a scan range of m/z 400–2000 in 
the MS scan. MS/MS data were analyzed using Mascot. 
The data were compared to the Uniprot Mouse data-
base, using trypsin digestion with up to three missed 
cleavages, a peptide tolerance of 5  ppm, and MS/MS 
tolerance of 0.3 Da. Acetylated N-termini and oxidation 
of methionine were included as variable modifications.
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Additional file 1: Fig. S1. (A) Western blot analysis of the changes in the 
level of expression of MeCP2‑E1 and E2 isoforms during brain develop‑
ment (n = 6). (B) Summary of thermal unfolding results for NTD‑MBD E1 
and NTD‑MBD E2 performed in different conditions (pH 7, pH8 and pH9 
and at pH7 in presence of methylated dsDNA or unmethylated dsDNA). 
(C) Fluorescence recovery after photobleaching (FRAP) to determine 
diffusion and binding kinetics of human wild type MeCP2‑E1 and E2 
in HEK293T. (1) Real time post‑bleach recovery of GFP tagged isoforms 
(bleaching 1000 ms/frame for 2 frames). Red lightening indicates bleach 
spots. (2) and (3) Comparative illustration of average half maximal recov‑
ery time and mobile fraction of wild type MeCP2‑W1 and E2, respectively. 
Mean and S.E. are shown. (4) FRAP recovery curves normalized to 1, show‑
ing chromocenter recovery in 151 frames. 
Additional file 2: Fig. S2. A (1) Western blot showing the levels of total 
MeCP2 and MeCP2 isoforms upon SH‑SY5Y differentiation. (2) Expression 
changes of general (Sox2) and neuronal (Syt1, Syn1, Tubb3) differentia‑
tion markers as detected by Reverse Transcriptase quantitative Poly‑
merase Chain Reaction (RT qPCR). Data represent mean ± S.E.M (n = 3). 
(B) (1) Western blot showing untransfected HEK 293 cells and HEK 293 
cells expressing 3xFlag‑MeCP2 E1 and 3xFlag‑MeCP2 E2. Immunoblots 
were performed using the following antibodies: panMeCP2, MeCP2‑E1 
and MeCP2‑E2 (Three upper panel). Equal loadings were assessed by 
Coomasie blue gel staining (lower panel). (2) Western blot performed 
after immunoprecipitation of endogenous MeCP2‑E1 and MeCP2‑E2 
from whole brain lysates. Normal rabbit IgG was used as negative control. 
Immunoprecipitated proteins were run in 10% gels to differentiate 
isoforms sizes and panMeCP2 antibody was used for staining. (3) Ponceau 
staining showing equal loadings of wild type (WT) and Adrian Bird’s knock 
out (KO) mouse (60) brain samples. Samples were run on 12% SDS PAGE 
(66). (4) Western blots of Total MeCP2, MeCP2‑E1 and MeCP2‑E2 antibod‑
ies. H4 was used as a normalizer. 
Additional file 3: Fig. S3. (A) Summary table showing the amount of 
ChIP seq mapped reads per sample and number of reads post filtering. 
(B) Integrative genomics viewer (IGV) (23) profiles of E1 and E2 ChIP‑seq 
based on sequence reads of each sample. Data represent a 20 Mb region 
of chromosome 17. Numbers in the right of each track represent track 
heights. 
Additional file 4: Fig. S4. MeCP2 isoforms functional networks as deter‑
mined by using STRINGv10 software.
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